Related Experiment Video
Updated: Jan 7, 2026
07:20
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
37.1K
Biomarkers.
1Gates Ventures, Seattle, WA, USA.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
Summary
The Global Neurodegeneration Proteomics Consortium (GNPC) created a large dataset of over 300 million protein measures from 40,000 analyses. This resource aims to advance understanding and develop biomarkers for neurodegenerative diseases like Alzheimer's and Parkinson's.
Area of Science:
- Neuroscience
- Proteomics
- Biomarker Discovery
Background:
- Understanding neurodegenerative diseases (Alzheimer's, Parkinson's, ALS, FTD) is limited, hindering biomarker and treatment development.
- Large, harmonized patient-derived datasets are crucial for unraveling complex neurodegenerative biology.
- The Global Neurodegeneration Proteomics Consortium (GNPC) established a major proteomic dataset with ~300 million measures from ~40,000 biosamples.
Purpose of the Study:
- To create a large, harmonized proteomic dataset for neurodegenerative disease research.
- To overcome legal, technological, and incentive barriers to data sharing.
- To provide a global resource for researchers to analyze proteomic and clinical data.
Main Methods:
- Harmonized 23 heterogeneous clinical and proteomic datasets.
- Addressed barriers to open data sharing.
- Hosted the harmonized dataset on the Alzheimer's Disease Data Initiative's AD Workbench.
Main Results:
- The Harmonized Dataset (HDS) version 1 contains ~40,000 proteomic analyses (SomaScan, Olink, mass spectrometry).
- All samples include 50 phenotypic indicators (demographics, cognitive, clinical, genotype).
- Data is securely hosted on AD Workbench with compute resources for >100 researchers.
Conclusions:
- The GNPC dataset is one of the largest protein biomarker discovery efforts for neurodegenerative diseases.
- Preliminary analyses will identify diagnostic and predictive proteomic biomarker signatures.
- Findings will advance understanding of pan-neurodegeneration and disease-specific states.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516